Novel anti-inflammatory peptides based on chemokine – glycosaminoglycan interactions reduce leukocyte migration and disease severity in a model of rheumatoid arthritis by McNaughton, Emily et al.
                          McNaughton, E., Eustace, A., King, S., Sessions, R., Kay, A., Farris, M., ...
Middleton, J. (2018). Novel anti-inflammatory peptides based on chemokine
– glycosaminoglycan interactions reduce leukocyte migration and disease
severity in a model of rheumatoid arthritis. Journal of Immunology, 200(9),
3201-3217. https://doi.org/10.4049/jimmunol.1701187
Peer reviewed version
Link to published version (if available):
10.4049/jimmunol.1701187
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via The American Association of Immunologists, Inc. at http://www.jimmunol.org/content/200/9/3201. Please
refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Novel anti-inflammatory peptides based on chemokines 
 
 1 
Novel anti-inflammatory peptides based on chemokine – 
glycosaminoglycan interactions reduce leukocyte migration and 
disease severity in a model of rheumatoid arthritis 
 
Emily F. McNaughton*, Andrew D. Eustace*, Sophie King*, Richard B. Sessions*, 
Alasdair Kay§, Michele Farris‡, Robert Broadbridge‡, Oksana Kehoe§, Andreas J. 
Kungl† & Jim Middleton* 
 
*  University of Bristol, UK 
§  University of Keele, UK 
‡  Peptide Protein Research Ltd, UK 
†  Karl-Franzens University, Austria 
 
Corresponding author; email: jim.middleton@bristol.ac.uk 
 
Author contributions:  JM conceived and designed the study.  EFM, ADE, SK, OK 
and AK performed experiments and analysed data.  RBS assisted with peptide 
modelling and design.  MF and RB provided peptide synthesis facilities and peptide 
chemistry consultation.  AJK advised and contributed to IFT data.  EFM and JM 
wrote the manuscript. 
 
Funding was provided by the Biotechnology and Biological Sciences Research 
Council (BBSRC), Peptide Protein Research (PPR Ltd), Bristol Research into 
Alzheimer’s and Care of the Elderly (BRACE) and British Microcirculation Society 
(BMS). 
Novel anti-inflammatory peptides based on chemokines 
 
 2 
Abstract 
Inflammation is characterised by the infiltration of leukocytes from the circulation 
and into the inflamed area.  Leukocytes are guided throughout this process by 
chemokines.  These are basic proteins which interact with leukocytes to initiate their 
activation and extravasation via chemokines receptors.  This is enabled through 
chemokine immobilisation by glycosaminoglycans (GAGs) at the luminal endothelial 
surface of blood vessels.  A specific stretch of basic amino acids on the chemokine, 
often at the C-terminus, interacts with the negatively charged GAGs which is 
considered an essential interaction for the chemokine function.  Short chain peptides 
based on this GAG binding region of the chemokines CCL5, CXCL8 and CXCL12 
were synthesised using standard Fmoc chemistry.  These peptides were found to bind 
to GAGs with high affinity which translated into a reduction of leukocyte migration 
across a cultured endothelial monolayer in response to chemokines.  The leukocyte 
migration was inhibited upon removal of heparan sulphate (HS) from the endothelial 
surface and was found to reduce the ability of the chemokine and peptide to bind to 
endothelial cells in binding assays and to human rheumatoid arthritis (RA) tissue.  
Furthermore, control peptides lacking the basic amino acids showed reduced 
interaction with HS and no anti-chemotactic ability for leukocytes across an 
endothelial monolayer.  The data suggest that the peptide competes with the wildtype 
(WT) chemokine for binding to GAGs such as HS and thereby reduces chemokine 
presentation and subsequent leukocyte migration.  Furthermore, the lead peptide 
based on CXCL8 could reduce the disease severity and serum levels of the pro-
inflammatory cytokine TNF in a murine antigen induced arthritis model. Taken 
together, evidence is provided for interfering with the chemokine – GAG interaction 
as a relevant therapeutic approach.  The use of site specific sequences of chemokines 
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to target GAGs and compete with WT chemokines is a novel and promising avenue 
for the field. 
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Introduction 
 
Inflammation is a necessary process to prevent infection and the effects of injury on 
the body and its conclusion requires a controlled self-limiting process. When it 
becomes unresolved and chronic it becomes destructive leading to inflammatory 
disease.  Leukocyte extravasation is a characteristic of inflammation and the 
recruitment of leukocytes from the circulation into the inflamed tissue is a multi-step 
process (1).  Firstly, leukocytes are loosely tethered to the endothelium of blood 
vessel walls where they roll and interact with endothelial cell (EC) bound chemokines 
and adhesion molecules such as selectins.  The interaction with chemokines activates 
leukocyte integrins enabling the leukocyte to mediate firm adhesion to the 
endothelium.  Chemokines also stimulate leukocyte crawling on the endothelial 
surface and migration across the ECs, the basement membrane and into the 
extracellular matrix of the tissue (2).  Once within the tissue, leukocytes normally 
perform various beneficial immune duties such as tissue repair and pathogen 
elimination.  Due to the potentially destructive nature of leukocytes, tight regulation is 
required otherwise inflammatory disease can ensue.  Chemokines play a role in the 
regulation of the inflammatory process by interactions with two binding molecules: 
G-protein coupled receptors (GPCRs) and GAGs.  
 
Chemokines are small (8-10 kDa) chemoattractant cytokines involved in numerous 
physiological processes such as angiogenesis but mainly their role lies in the 
chemoattraction of migratory cells (3). Thus far, around 45 chemokines have been 
identified and are classified into four groups (C, CXC, CX3C and CC) based on the 
pattern of cysteine residues in the ligands (4).  Despite the range and diversity of 
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chemokines with regards to their homeostatic or inflammatory function, they have a 
remarkably similar tertiary structure consisting of a conformationally disordered N-
terminus, a long N-loop followed by a single turn 310 helix, a three stranded 
antiparallel β-sheet and a C-terminal α-helix (5).  The flexible N-terminal region is 
central to receptor activation since studies have shown that mutations or truncation of 
this region results in altered leukocyte activity (6, 7).  In vitro studies have shown that 
more than one chemokine can bind to a given receptor and that several receptors are 
able to bind a given chemokine hinting that a large amount of redundancy takes place.  
However, in vivo, the interaction seems to be more specific, it has been suggested that 
chemokine “redundancy” is in fact more likely  “finely tuned” (8).  Different ligands 
can activate distinct signalling pathways following binding to the same receptor.  For 
example, both CCL19 and CCL21 induce chemotaxis of CCR7 expressing cells, yet 
only CCL19 is able to induce receptor downregulation (9).  As we learn more about 
chemokines, they may prove to be attractive therapeutic targets in the clinic. 
 
The second and less well characterised interaction of chemokines is with 
carbohydrates, namely GAGs.  GAGs are long, linear and heterogenous structures 
consisting of repeating disaccharide units which vary in the basic composition of the 
saccharide, the linkage to the core protein, acetylation and N- and O-sulphation (10).   
GAGs are ubiquitously expressed although different types (heparan-, dermatan-, 
chondroitin- and keratan- sulphate) may be found on cell surfaces within the 
glycocalyx and throughout the extracellular matrix of all mammalian tissues. GAGs 
can be surface bound or shed as soluble ectodomains (11); a process which 
dramatically changes their function (12). Their chain lengths can range from 1 to 
25,000 disaccharide units thus together with structural variation in sulphation 
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patterns, this presents an immense level of diversity.  This amount of diversity 
suggests an element of control and specificity when binding their biological ligands.  
GAGs are usually covalently attached to a protein core (with the exception of 
hyaluronic acid and heparin) to form a proteoglycan (PG).  The most ubiquitous of 
these PGs are heparan sulphate proteoglycans (HSPGs) which are classified into 5 
groups of core proteins which range in size from 32 to 500 kDa.  The most abundant 
form are the syndecans that contain a transmembrane region anchoring them to the 
cell surface.  In contrast, the glypicans are anchored to the cell surface via glycosyl-
phosphatidylinositol groups and the other three (perlecan, agrin and collagen XVIII) 
do not have direct links to the cell membrane but remain closely associated with it 
(10). The composition and spacing of the GAG chains on the protein is dependent on 
the cell type and correlates with different physiological responses of the cell (13).  
The differential expression of PGs on particular cells allows them to dynamically 
function and adapt within the local microenvironment exhibiting an aspect of 
functional specificity. 
 
GAG chains have been implicated in leukocyte transmigration  and one GAG in 
particular is believed to have multiple roles in the extravasation process:  heparan 
sulphate (HS) (14).   HS is the most abundant endothelial GAG and composes 50-
90% of total endothelial PGs (15).  HS has been implicated in binding to a wide range 
of proteins some of which include cytokines, adhesion molecules, proteases and 
growth factors.  Interaction of chemokines with HS can protect them from proteolysis 
(16) and induce them to oligomerise; high order oligomers are thought to be required 
for maximal chemokine activity (17).  Furthermore, the interaction establishes 
chemokine gradients for migrating leukocytes by being bound and presented at the 
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endothelial luminal surface (18) and HS is involved in the transcytosis of chemokines 
across the EC layer to be displayed at the luminal surface (18).  Leukocyte crawling 
also involves a chemokine – HS interaction and is critical for the leukocyte to find 
optimal sites to emigrate (2).  One might consider the subendothelial basement 
membrane represents a formidable barrier to leukocyte extravasation, often being in 
the range of 20 nm -100 nm thick, yet it is also rich in extracellular HSPGs.  This 
complex network of extracellular HSPGs such as perlecan, agrin and type XVIII 
collagen can serve to bind and sequester proteins that regulate leukocyte migration 
such as chemokines thereby contributing to leukocyte diapedesis (14).  Hence 
chemokine interaction with HS is involved in several key stages of leukocyte 
extravasation. 
 
The GAG binding motif on chemokines typically takes the form XBBXBX in CC 
chemokines (19) or XBBBXXBX in others where B represents a basic and X 
represents any non-basic amino acid (20).  In general, these motifs are found in a 
separate location from the specific receptor binding domain, and often within the C-
terminus.  Although positively charged chemokines have a favourable charge 
interaction with negatively charged GAGs, several lines of evidence suggest that 
more than non-specific electrostatic forces drive this interaction. For example, acidic 
chemokines such as CCL3 and CCL4 also bind GAGs (21) and it is thought that 
specificity of the GAG-chemokine interaction is introduced by Van der Waals and 
hydrogen-bond forces (10).  The GAG binding function of chemokines has been 
shown to be essential for optimal chemokine activity in vivo (19, 22-25).  For 
example, when CXCL8 is truncated of its HS-binding C-terminal helix, it fails to bind 
heparin and has impaired leukocyte activation and receptor-binding properties (26).  
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The truncation also shows reduced transcytosis across endothelial cells and luminal 
surface presentation to blood leukocytes, resulting in reduced leukocyte 
transmigration (18, 27). 
 
Chronic inflammation is also characterised by changes in GAG patterns (28).   
Changes in cell-surface and secreted GAGs in cancer has been shown to strongly 
influence the phenotype of the tumour, allowing them to control growth rates, 
invasiveness and metastatic potential (29). Moreover, a CXCL8 binding site on 
endothelial syndecan-3 is induced in the synovium of rheumatoid arthritis (RA) 
patients (30).  Furthermore, in an animal model of RA, syndecan-3 functions in 
endothelial chemokine presentation and leukocyte recruitment suggesting a role for 
this HSPG in leukocyte trafficking into the inflamed tissue (31).  Altered expression 
of endothelial GAGs has been observed in numerous other chronic inflammatory 
disorders including atherosclerosis (32) and inflammatory bowel disease (33).   This 
could promote the binding and presentation of chemokines that are selective for the 
particular GAG sequences expressed therefore contributing to a site-specific 
localisation of chemokines (34).  This suggests an element of control over the 
function of chemokines by HS. 
 
Clearly the GAG binding capability of chemokines is of importance in the multitude 
of steps involved in leukocyte extravasation.  The potentially specific and unique 
interactions that chemokines have with discrete GAG sequences are as yet largely 
unexplored.  Due to the number of diseases in which chemokines have been 
implicated, blockade of chemokine function seems an attractive strategy. This study 
aims to obtain more insight into the GAG binding regions of particular chemokines 
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namely CCL5, CXCL8 and CXCL12γ and their functional roles.  All of these 
chemokines are known to interact with HS and the HS binding domains are well 
established (20, 35, 36).  These chemokines were chosen based on the cell types they 
interact with i.e. CCL5 is largely chemotactic for monocytes, CXCL8 for neutrophils 
and the relatively newly discovered CXCL12γ has a uniquely rich HS-binding C-
terminus and appears to stimulate migration of lymphocytes.  Using a novel approach, 
we chemically synthesised peptide chains based only on the GAG binding regions of 
each of these chemokines and tested their abilities to bind to HS and compete with 
chemokines in transendothelial migration assays.  Sequences where the known HS 
binding residues including lysine and arginine were altered to non-charged residues 
such as glycine, serine and alanine were synthesised to act as controls.  The lead 
peptide based on CXCL8 was assessed for binding to GAGs in EC lines and human 
RA synovium.  It was then tested in a murine antigen induced arthritis (AIA) model.  
This strategy could improve future prospects for exploiting GAGs as therapeutic 
targets and other strategies for targeting chemokine-GAG interactions. 
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Materials and Methods 
Peptide modelling 
The crystal structures of each chemokine were taken from the Protein Data Bank 
(PDB):  CXCL8 (PDB code: 3IL8), CCL5 (PDB code: P_1U4L) and CXCL12 (PDB 
code: 2NWG).  Using the biopolymer module of molecular modelling program, 
Insight II (version 2005 by Accelrys), each of the chemokines was displayed and the 
peptides based on chemokines were structurally defined.  The chemokines were 
rendered using a space-filling model (cpk representation) to represent the atoms 
present and are modelled as the biologically relevant dimers.  Peptides based on 
chemokines were modelled to show the amino acid sequences of the peptide 
highlighted on the particular region of the chemokine where they are located.  The 
structure of peptide (p)CXCL12-1 required the construction of C-terminal alpha 
helices found in the CXCL12γ isoform which were modelled onto residue 67 and 
extended to 98 residues.  The design of pCXCL8-4 was based on the C-terminal alpha 
helices spliced together with a linker sequence GSGSG.  The GNU image 
manipulation program (GIMP) version 2.8 was used to manipulate images and 
perform format conversion. 
 
Peptide synthesis 
All reagents and solvents for peptide synthesis were purchased commercially from 
Sigma-Aldrich, Gillingham, UK and peptides were synthesised at PPR Ltd, Bishops 
Waltham, UK.  Solid phase peptide synthesis was carried out on an automated peptide 
synthesiser Symphony® employing standard Fmoc chemistry.  Peptides were cleaved 
from the solid support and purified using reverse-phase HPLC.  The crude peptide 
product was loaded onto a preparative C-18 Axia silica column typically running a 
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linear gradient of water and acetonitrile buffers, each containing 0.1% trifluoroacetic 
acid (TFA) at a gradient routinely run from 20% to 60% acetonitrile (depending on 
the peptide) for 1 hour at a flow rate of 20 ml/min whilst monitoring the eluent at 225 
nm. The collected fractions were lyophilised before analytical techniques such as 
liquid chromatography – mass spectrometry (LCMS) were employed to give an 
overall purity read out.  Peptides were > 90% pure.  Peptide sequences can be seen in 
Table 1. 
 
Some peptides were N-terminally modified by the addition of tags such as biotin and 
FITC (fluorescein isothiocyanate).  These were coupled manually to the last amino 
acid of the N-terminus using an aminohexanoic acid (Ahx) linker overnight and the 
resulting peptide was cleaved from the resin as normal.  The lead peptide pCXCL8-1 
was capped at the C-terminus by using a resin functionalized with a modified Rink 
Amide linker and at the N-terminus with 50% acetic anhydride / pyridine in order to 
be used for intra-articular administration in vivo. 
 
Isothermal fluorescent titration 
The titration experiments were performed on a Fluoromax-4 Spectrofluorometer 
(Horiba, Kyoto, Japan) coupled to an external water bath to ensure constant 
temperature during the measurements. Protein fluorescence emission spectra were 
recorded over the range of 500 – 600 nm upon excitation at 495 nm. The slit widths 
were set at 3 nm for excitation and emission, scan speed at 500 nm/min and the 
temperature was set to 20°C. The use of concentrated GAG oligosaccharide stock 
solutions ensured a dilution of the protein sample less than 5%. Prior to collection of 
the initial (=unliganded) protein emission spectra, 100 nM protein solutions were 
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prepared from stock solutions and were equilibrated for 30 mins. Following 
equilibration, respective GAG ligands (HS [catalogue number: GAG-HS01], DS 
[catalogue number: GAG-DS01]; Iduron Manchester, UK) were added in 
concentrations ranging from 5 nM to 50 nM.  The protein / GAG solutions were then 
equilibrated for 1 min and fluorescence emission spectra were collected. For 
background correction the emission spectra of the respective GAG concentrations 
were collected in PBS buffer only. They were subsequently subtracted from protein 
emission spectra and the resulting curves were then integrated. The mean values 
resulting from 3 independent measurements were plotted against the concentration of 
the added ligand. The resulting binding isotherms were analysed by non-linear 
regression using the program Origin (Microcal Inc., Northampton, MA, USA) to the 
following equation describing a bimolecular association reaction, where Fi is the 
initial and Fmax is the maximum fluorescence value. Kd is the dissociation constant, 
and [protein] and [ligand] are the total concentrations of the chemokine/peptide and 
the GAG ligand: 
 
Cell culture 
Immortalised human bone marrow ECs (HBMECs), and human cerebral 
microvascular ECs (HCMEC/D3s) were both donated by Prof B. B Weksler, Cornell 
University, New York and support leukocyte transendothelial migration studies (37-
39).  HBMECs were maintained in DMEM-F12 (Lonza, Wokingham, UK) 
supplemented with 10% FBS (Invitrogen, Paisley, UK) and HCMEC/D3s in rat tail 
collagen type 1 (R&D Systems, Abingdon, UK) coated flasks (150 mg/ml in dH2O) 
using EBM-2 (Lonza) containing 1% penicillin-streptomycin (Invitrogen), 1% 
chemically defined lipid concentrate (Invitrogen), 1 ng/ml basic fibroblast growth 
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factor (bFGF; Sigma-Aldrich), 1.4 μM hydrocortisone (Sigma-Aldrich), 5 μg/ml 
ascorbic acid (Sigma-Aldrich), 10 mM HEPES (PAA Laboratories, Yeovil, UK), 5% 
FBS and 10 mM lithium chloride (Merck, Feltham, UK).  All ECs were incubated at 
37°C in a humidified incubator containing 5% CO2.  Cells were grown to 70% 
confluence before being used in the following experiments. 
 
HS Immunofluorescence 
ECs were seeded at a density of 2.5x105 in Nunc® Lab-Tek® 8-well chamber slides 
(Sigma-Aldrich) using 500 µl serum free medium and left to reach confluence for 24 
hours.  Some cells were treated with heparanase I (10 U/ml) and heparanase III (2 
U/ml; both from Sigma-Aldrich) as described by Whittall et al, (2013) for 1.5 hours at 
37°C to remove the HS.  Following the heparanase treatment cells were fixed with 
4% PFA for 10 mins before being incubated with 2 µg/ml mouse anti-human HS 
antibody (10e4; AMSBio, Abingdon, UK) for 1 hour in 2% BSA/PBS at room 
temperature (RT).  The cells were washed 3 times in PBS.  The primary antibody was 
detected by Alexa Fluor 488 goat anti-mouse IgM (1:200 in 2% BSA/PBS) and the 
cells washed before being counterstained in DAPI (2 µg/ml; 4',6-diamidino-2-
phenylindole) for 3 mins.  For a control, mouse IgM was used at an equivalent 
concentration in place of the primary antibody.  Slides were mounted using 
Hydromount (Fisher Scientific, Loughborough, UK) and visualised with a light 
fluorescence microscope (Leica DM LB) and analysed with Cell˄D software.  
 
Transendothelial migration 
Leukocyte isolation 
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For all leukocyte collection, a total of 20 ml blood was collected from healthy 
volunteers, after informed consent, into lithium heparin treated vacutainers.  To 
isolate polymorphonuclear (PMNs) cells the blood was centrifuged at 500 x g for 30 
mins with polymorphprep (Axis-Shield, Oslo, Norway) followed by the removal of 
mononuclear (MNs) cells and erythrocytes.  The remaining PMNs were washed with 
an equal volume of HBSS and dH2O for 10 mins at 400 x g followed by erythrocyte 
lysis using ammonium chloride solution (Stemcell Technologies, Cambridge, UK) for 
7 mins at 37˚C.  The PMNs were then harvested by centrifugation at 300 x g for 5 
mins, resuspended in 0.1% BSA in RPMI-1640 (Lonza) and held at 4˚C until 
required.  For mononuclear cell isolation, the same process applied except the MNs 
were harvested after initial centrifugation and the PMNs and erythrocytes were 
discarded. 
 
Neutrophil migration through an endothelial layer 
A total of 2.5 x 105 ECs in 500 µl cell growth medium were cultured on 3 µm pore 
transwell filters (Fisher Scientific) in a 24-well flat-bottomed microplate (Corning® 
Costar®, Sigma-Aldrich) with 800 µl of cell growth medium in the basal chambers 
until confluence was reached (24 hours at 37°C). The solution in the apical chamber 
was replaced with 500 µl fresh serum-free medium and the solution in the basal 
chamber was replaced with a solution of serum-free medium containing 100 ng/ml 
CXCL8 or CXCL12γ; for controls, serum-free medium containing no CXCL8 or 
CXCL12γ was used.  The samples were incubated at 37°C for 30 mins for endothelial 
activation to occur as described by Whittall et al. 2013. ECs were activated by 
incubating monolayers with the following chemokines:  recombinant human CXCL8, 
CCL5 (both from Peprotech) and CXCL12 (R&D Systems) at concentrations of 100 
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ng/ml in serum free medium for 30 mins at 37°C (39).  The negative controls 
contained no chemokines.  Monolayers were established by optimising seeding 
density of ECs and allowing to reach confluence over 24 hours.  At this time point the 
trans endothelial electrical resistance (TEER) value was maximum (using an EVOM2 
voltmeter) and experiments were carried out identically thereafter.  A total of 5 x 105 
PMNs were then added to the apical chambers, followed by incubation at 37°C for a 
further 30 mins in continued presence of CXCL8 or CXCL12γ.  PMN migration was 
quantified by determining the number of neutrophils that had migrated through to the 
basal chamber in 30 mins by manual counting using a disposable haemocytometer 
(Immune Systems, Torquay, UK) and displayed as a percentage of transendothelial 
migration when compared to chemokine alone. 
 
Mononuclear cell migration through an endothelial layer 
MN cell migration was carried out in an identical manner to PMN cell migration with 
three notable differences.  The chemokine was human recombinant CCL5 (100 
ng/ml), the ECs were cultured on 5 µm pore transwell filters (Fisher Scientific) and a 
total of 4 x 105 MNs were added to the apical chamber, followed by incubation at 
37°C for 3 hours following addition of MNs in continued presence of CCL5. 
 
Inhibiting leukocyte migration using peptides 
To assess the ability of peptides based on CXCL8, CXCL12γ and CCL5 to inhibit 
leukocyte migration, a range of concentrations (0.5, 5, 50, 500 and 5000 nM) were 
added to the basal chamber of the transwell system at the same time as the 
corresponding chemokine.  Serum-free medium containing chemokine alone was used 
as the positive control and containing no chemokine as the negative control.   The 
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ability of the test peptide at inhibiting leukocyte migration was also compared with a 
peptide control (Table 1; a sequence containing charged HS binding sites i.e. Lys and 
Arg to non-charged amino acids i.e. Ala, Gly or Ser) using the HCMEC/D3 cell line. 
 
Inhibiting leukocyte migration using heparanases 
To assess the role of HS in leukocyte migration, ECs in the transwell chambers were 
treated with heparanase I and III as described above and by (39).  Following 
incubation with heparanases, relevant chemokines were added and leukocyte 
transendothelial migration was carried out as before.   
 
ELISA-like competition assay 
GAG binding plates (Iduron) were coated with 25 µg/ml of HS (Sigma: catalogue 
number H7640-10MG) in standard assay buffer (100 mM NaCl, 50 mM sodium 
acetate, 0.2% v/v Tween 20, pH 7.2) overnight at RT.  After washing the plate three 
times with standard assay buffer, the wells were blocked with blocking solution (1% 
w/v BSA in PBS) for 1 hour at 37°C and the wash step repeated.  CXCL8 (Peprotech, 
London, UK) was titrated for detection and used thereafter at 0.75 µg/ml in blocking 
solution.  CXCL8 was incubated with different competitor concentrations of peptide 
(pCXCL8-1: 0.5, 5, 50, 500, 5000 nM) for 2 hours at 37°C in triplicate.  Unbound 
chemokine and peptide was removed by three wash steps followed by addition of a 
220 ng/ml solution of biotinylated anti-human CXCL8 (Peprotech) in blocking 
solution for one hour at 37°C.  Following three more washes, 220 ng/ml ExtrAvidin-
alkaline phosphatase (Sigma) in blocking solution was added to the wells for 30 mins 
at 37°C.  The plate was washed three times then 200µl of a development reagent, 
SigmaFAST p-Nitrophenyl phosphate (Sigma) was added and left to develop for 40 
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mins at RT.  The optical density (OD) was then read at 405 nm using a 
spectrophotometer.  Percentage inhibition of chemokine binding to HS was calculated 
as follows, with the control being standard assay buffer only: 
 
 
 
 
Cellular binding assays by flow cytometry 
ECs were detached from T75 flasks and incubated with labelled chemokine or peptide 
in FACs buffer (1% BSA/PBS) for 1 hour on ice.  The peptide was titrated and used 
at 5 µg/ml of FITC labelled pCXCL8-1 (fpCXCL8-1) or control pCXCL8-1c 
(fpCXCL8-1c). 
 
To assess CXCL8 binding to ECs, CXCL8 was labelled with Atto 425 (Bio-Techne, 
Abingdon, UK) according to the manufacturers instructions.  The fluorescently 
labelled CXCL8 was titrated and subsequently used at 50 µg/ml (5.3 nM) in FACs 
buffer.  For a control cells were incubated with FACs buffer only.  Binding to ECs 
was carried out as before, for 1 hour on ice.  In order to assess whether pCXCL8-1 
could compete with CXCL8 for binding sites, 0.5 nM, 5 nM and 50 nM of unlabelled 
peptide was added at the same time as fluorescent CXCL8.   
 
To confirm whether CXCL8 and the peptide pCXCL8-1 was binding to HS, cells 
were pre-treated with heparanase I and III as described previously (39) before the 
addition of fluorescently labelled CXCL8 or peptide.  
 
Percentage inhibition = 
OD (x nM chemokine + y nM peptide) – OD (control sample)
OD (x nM chemokine) – OD (control sample)
X 100
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Following the incubations cells were washed by spinning down with FACs buffer 
twice at 500 x g for 5 mins.  Cells were then analysed for binding using a NovoCyte® 
flow cytometer and analysed using NovoExpress® software.  Cells were gated on 
forward scatter side scatter on all viable cells and then a second gate was placed on 
singlets.  To assess binding, forward scatter-area and FITC-area were used to gate on 
positive and negative cells of peptide binding and BV510-area was used to detect 
Atto425 emission of CXCL8 binding. 
 
Tissue binding assays in situ 
Synovial tissue was obtained from Keele University with full ethical approval from 
the Birmingham, East, North and Solihull Research Ethics Committee (study ID:  
11/WM/0035).  Sections were cut at 10 µm using a cryostat and mounted onto 
polylysine slides (Thermo Fisher) and stored at -20°C until use.   
 
Sections were equilibrated at RT for 30 mins prior to use and then with ice cold 
binding buffer (0.1% BSA in HBSS containing 10 mM HEPES) for 5 mins. Labelled 
peptide and chemokine were added for one hour in binding buffer and these were 
biotinylated pCXCL8-1 (bpCXCL8-1; 5 µg/ml) which was detected with streptavidin 
Alexa Fluor 488 (1:200; BioLegend, London, UK) and Atto 425 (Bio-Techne) 
labelled CXCL8 (5 µg/ml/0.53 nM); Peprotech).  In each case a double stain was 
performed with Von Willebrand factor antibody (15.5 µg/ml; DAKO, Cambridge, 
UK) followed by a goat anti-rabbit Alexa Fluor 594 (1:400; Thermo Fisher).  For 
controls, binding buffer in the absence of bpCXCL8-1 and Atto 425 labelled CXCL8 
were used and rabbit IgG (15.5 µg/ml; DAKO) in the place of anti-Von Willebrand 
factor. 
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In order to assess whether pCXCL8-1 could compete with CXCL8 for binding sites, 
an equimolar amount of unlabelled pCXCL8-1 (0.5nM) was added at the same time 
as Atto 425 labelled CXCL8.  To confirm whether CXCL8 was binding to HS, tissue 
was pre-treated with heparanase I and III, as described previously (40), before the 
addition of labelled CXCL8.  For a control, tissue was treated with binding buffer 
only. 
 
Finally, sections were washed in binding buffer and then counterstained with DAPI 
(2µg/ml in dH2O) for 5 mins.  Sections were rinsed, mounted in Hydromount 
(Thermo Fisher) and visualised with a fluorescence light microscope (Leica DM LB) 
and analysed with Cell˄D software.  
 
Murine antigen induced arthritis (AIA) 
Animals 
Experiments were conducted in 7 to 10 - week-old inbred male C57Bl/6 WT mice. 
Animals were housed and maintained under conventional management at animal 
facilities at Liverpool John Moores University, UK. Procedures were performed with 
ethical approval from the Home Office, UK, and were carried out under the project 
licence PPL 40/3047. 
 
Induction of murine AIA 
Murine AIA was induced as described previously (31, 41).  All reagents used for AIA 
induction were from Sigma-Aldrich.  In short, mice were immunised subcutaneously 
with 1 mg/ml of methylated BSA (mBSA) emulsified with an equal volume of 
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Freund’s complete adjuvant and injected intraperitonealy with 100 μl heat-inactivated 
Bordetella pertussis toxin, the subsequent immune response was boosted one week 
later.  Three weeks after the initial immunisation, AIA was induced by intra-articular 
injection of 10 mg/ml mBSA into the right knee joint and PBS into the left knee joint 
to serve as a control.   
 
Intra-articular injection of pCXCL8-1aa 
6 hours post arthritis induction, 10 µl of peptide (pCXCL8-1aa) (5 µg) and control 
peptide (pCXCL8-1caa) were injected intra-articularly (0.5 ml monoject (29G) insulin 
syringe, BD Micro-Fine, Franklyn Lakes, USA) into the right knee of 10 animals 
respectively.  At the end of experiments (day 3 and day 7 post induction of AIA, n=5) 
animals were sacrificed and joints were collected for histology. 
 
Histological assessment 
Joints were fixed in neutral buffered formal saline and decalcified with 10% formic 
acid for 72 hours before embedding in paraffin.  Mid-sagittal sections (2µm 
thickness) were cut and stained with haematoxylin and eosin (H&E) for scoring of 
degree of infiltration (normal = 0 – severe = 5), synovial hyperplasia in the lining 
layer (0-3) and cellular exudate in the joint space (0-3) as described previously (31, 
41).  Sections were stained with toluidine blue for scoring of degree of cartilage 
depletion (0-3) based on PG loss.  Blind scoring was undertaken and all parameters 
were pooled to give an arthritic index (mean ± SEM). 
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Neutrophil infiltration was quantitated by counting the number of neutrophils in the 
synovium in H&E sections in 5 random fields of view at x1000 magnification as 
described previously (31). Means and standard errors were then calculated. 
 
TNFα assay 
Using a mouse TNFα ELISA Ready-SET-Go! Kit (eBioscience, Altrincham, UK) the 
serum concentration of TNFα was measured according to the manufacturer’s 
instructions. 
 
Statistical analysis 
Statistical analysis was carried out on GraphPad Prism 5.0.  A one-way ANOVA 
followed by Dunnett’s post hoc test was used for multiple comparisons and a two-
tailed Student’s t-test for comparisons of two variables. p-values less than 0.05 were 
deemed as significant. 
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Results 
 
Modelling and synthesising peptides based on the HS-rich binding domain of 
chemokines 
Chemokines were chosen based on the cells they interact with and their roles in acute 
or chronic phases of inflammatory diseases.  CXCL8 (Figure 1A) is a potent 
chemoattractant of neutrophils, CCL5 (Figure 1E) is largely associated with the 
chemotaxis of monocytes and T cells, and CXCL12γ (Figure 1G) for lymphocytes, 
the dysregulation of each resulting in upregulated leukocyte migration.  The residues 
of the chemokines implicated in GAG binding have been shown to be contained 
within the C-terminal alpha helix of CXCL8 (35) and CXCL12γ (36) and within the 
40s loop of CCL5 (20).  Therefore, our peptides were modelled on these particular 
regions without the inclusion of the tertiary chemokine structure.  In addition, control 
peptides were synthesised whereby the positively charged amino acids such as lysine 
and arginine were substituted with non-charged amino acids such as alanine, glycine 
and / or serine.  The sequences can be seen in Table 1. 
 
A number of CXCL8 peptides were modelled to include varying amounts of HS 
binding domains.  A 10 amino acid peptide (pCXCL8-1) and a 15 amino acid peptide 
(pCXCL8-2) were synthesised based on the C-terminal alpha helix and included 
Lys64, Lys67 and Arg68 (pCXCL8-1) plus the addition of Arg60 in pCXCL8-2 as seen 
in Figure 1B.  CXCL8 also has another HS binding domain located within the 
proximal loop: Lys20.  Therefore, a longer 54 amino acid peptide was synthesised to 
include all of these HS binding sites (pCXCL8-3; Figure 1C).  As CXCL8 exists in 
both monomeric and dimeric form, a further dimeric peptide was modelled to include 
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both alpha helices held in place with a linker molecule as seen in Figure 1D, 
comprising 41 amino acids in total (pCXCL8-4). Hence, this peptide therefore had a 
total of 8 HS binding sites.  The lead peptide pCXCL8-1 was modified for in vivo 
work (pCXCL8-1aa) in order to protect it from proteolytic degradation and reduced 
half-life.  Due to the direct intra-articular administration of the peptide it was decided 
that the peptide would not need increased plasma half-life so instead it was opted to 
protect the peptide at the terminal regions. In order to do this, the peptide was 
amidated and acetylated thereby altering the peptide ends into an uncharged state 
(Table 1).  This more closely mimics the native protein and these modifications would 
increase the metabolic stability of the peptide as well as its ability to resist enzymatic 
degradation. 
 
Peptides based on CCL5 were chosen to include varying amounts of the 40s loop.  
Three peptides in total were designed.  pCCL5-1 comprised four amino acids  
44 RKNR47 and this was extended in the N-terminal direction to increase the overall 
mass to include Thr43 (pCCL5-2; five amino acids) and Val42 (pCCL5-3; six residues) 
as seen in Figure 1F and Table 1. 
 
The peptide based on CXCL12γ (pCXCL12-1) takes advantage of its enriched C-
terminal alpha helix.  The 30 amino acid helix contains 18 basic residues, 9 of which 
are clustered into 4 acknowledged HS-binding domains and therefore the design for 
the peptide was simply to incorporate the 30 amino acids of this unique C-terminus 
(Figure 1H and Table 1).   
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Peptides based on chemokines bind to HS with high affinity 
The affinity of the peptide interaction with HS and DS was determined by isothermal 
fluorescent titration. Peptides or intact chemokine were labelled on the N-terminus 
with FITC (f) and fluorescence quenching was measured upon interaction with HS or 
DS.  This was repeated for control peptides where the putative HS binding sites had 
been altered to non-charged amino acids such as glycine, serine and alanine (Table 1).  
The resulting binding isotherms (Figure 2) were analysed by non-linear regression 
giving the Kd values shown in Table 2.   
All measured fCXCL8 peptides gave a higher affinity (lower Kd) than WT fCXCL8.  
WT fCXCL8 bound to HS with a Kd of 128 nM whereas fpCXCL8-1 and -2 gave 
values of 15 nM and 61 nM respectively.  The modified version of fpCXCL8-1 
(fpCXCL8-1aa) bound tighter than WT fCXCL8 although weaker than fpCXCL8-1 
(by approximately 4 fold), which is attributed to the modifications at the N- and C- 
termini.  Interestingly fpCXCL8-1, with 3 HS binding domains, had a 4 fold higher 
affinity for HS than fpCXCL8-2, with 4 HS binding domains.  fpCXCL8-1 also 
exhibited some selectivity for HS over DS (15 nM compared with 44 nM) similar 
behaviour to WT fCXCL8, whereas fpCXCL8-2 binds with similar affinity to both 
(61 nM compared to 52 nM).  Control peptides for fpCXCL8-1, fpCXCL8-1aa and 
fpCXCL8-2 showed no significant interaction with HS (Figure 2B-D) and therefore 
no Kd values could be calculated.  Quenching around 10% and late saturation of FITC 
fluorescence is indicative of a very weak and / or a non-specific interaction, thus 
highlighting the importance of the positively charged amino acids for GAG 
interaction.  
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The peptide based on CCL5, pCCL5-3, exhibited a strong affinity for HS with a Kd 
value of 8 nM.  This peptide showed selectivity for HS over DS (8 nM compared to 
148 nM).  As can be seen in Figure 2E, the control peptide showed <10% FITC 
quenching, again highlighting the importance of the positively charged amino acids 
associated with GAG binding.   
 
Due to the unique C-terminus of CXCL12γ, one would assume strong affinity for 
GAGs as confirmed by IFT measurements.  pCXCL12-1 gave a Kd values of 2 nM 
and 3 nM to HS and DS respectively (Figure 2F).   Interestingly, the control peptide 
for pCXCL12-1 showed some interaction with HS as indicated by the initial increase 
of the curve.  However, this interaction appeared to be non-specific due to the lack of 
saturation of FITC fluorescence.  The control peptide did contain positively charged 
amino acids that are reported to be uninvolved with GAG binding however these 
could be giving rise to some interaction with HS seen here. 
 
HS is a key player in leukocyte migration and for chemokine binding 
Before assessing the ability of peptides to bind to cellular HS and prevent leukocyte 
migration, it was necessary to determine the distribution of HS on ECs and elucidate 
the importance of this GAG during leukocyte transendothelial migration.  The 
distribution of HS was examined by immunofluorescence as seen in Figure 3A and B 
which shows a mesh-work like pattern of HS on the cellular surface.  When the cells 
were pre-treated with the enzymes heparanase I & III to degrade HS, the mesh-work 
like pattern was lost indicating a loss of HS on the cell surface (Figure 3C and D).  As 
a control, cells were stained with an IgM isotype control. 
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To examine the function of HS in leukocyte transendothelial migration, ECs were pre-
treated as before with HS degrading enzymes and leukocytes were then assessed for 
chemotaxis in response to chemokine in the basal chamber.  Chemokine 
concentrations were titrated (0-500 ng/ml) and used at 100 ng/ml.  As can be seen in 
Figure 3E, neutrophil migration was significantly reduced when treated with 
heparanase I & III compared to CXCL8 alone (p < 0.0001).  The amount of neutrophil 
migration was equivalent to baseline in the absence of CXCL8 (data not shown). 
However, when assessing the effect of heparanase treatment on the migration of 
monocytes to CCL5 (100 ng/ml), a lesser role for HS was observed although still 
significant (p = 0.0017).  From Figure 3F it can be seen that monocyte migration was 
reduced when HS was removed, however this reduction was ~40% compared to the 
80% for neutrophils.   
 
It is well established that GAGs are important in the binding and presentation of 
chemokines on the luminal surface of ECs (18, 27).  To assess whether this is the case 
for our EC transwell system we pre-treated ECs with heparanases and then tested the 
binding of fluorescently labelled CXCL8 or pCXCL8-1 by flow cytometry.  As can 
be seen in Figure 3G, CXCL8 bound to HCMEC/D3 cells significantly more than the 
control (FACs buffer only), exhibiting a total value of ~40% positive cells.  When the 
HCMEC/D3s were pre-treated with heparanase I&III, the number of CXCL8 positive 
cells was significantly reduced (p < 0.001).  These data agree with findings in Figure 
3E; that HS is crucial for the binding and presentation of CXCL8.  After confirming 
this was the case, we then wanted to see if the same was true for the peptide 
pCXCL8-1.  This peptide exhibited almost 100% binding to HCMEC/D3 cells 
whereas the control pCXCL8-1c showed no binding (Figure 3H), this again highlights 
Novel anti-inflammatory peptides based on chemokines 
 
 27 
the importance of the positively charged HS binding domains in the peptide for EC 
interaction.  This also agrees with IFT data that pCXCL8-1 has a higher affinity for 
HS than CXCL8 by the fact that pCXCL8-1 binds with a 2.5 fold increase in the 
percent of EC binding compared to CXCL8 (Figure 3G and H).   When the cells were 
treated with heparanases, the percentage positivity of pCXCL8-1 binding was 
significantly reduced (p<0.001) (Figure 3H).  
 
Peptides reduce leukocyte migration through an EC layer 
To characterise the anti-chemotactic ability of peptides based on chemokines, they 
were tested in an in vitro model of inflammation.  Using a transendothelial cell assay 
in two cell lines, the ability of the peptide to prevent leukocyte migration towards a 
chemokine stimulus was measured (Figure 4).  pCXCL8-1 significantly reduced 
neutrophil migration in the HCMEC/D3 cell line compared to the corresponding 
control peptide (Table 1) at all concentrations of peptide apart from 5000nM.  The 
optimum concentration appeared to be 0.5 nM of peptide with a reduction of 
neutrophil migration up to 60% (p < 0.001) compared to the absence of peptide.  The 
same peptide and concentration in the HBMEC cell line showed similar effects 
(p<0.05) although more variability was observed.  
 
In order to characterise the modified version of pCXCL8-1 (pCXCL8-1aa), it was 
tested in the transwell system before being used in vivo.  As indicated by the graphs 
there was a significant reduction of neutrophil migration in both cell lines again 
between the 0.5 nM – 500 nM range of peptide.  These results display a similarity to 
pCXCL8-1 data confirming that the modifications have not affected the biological 
activity of the peptide.   
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The larger pCXCL8-2 peptide was able to reduce neutrophil migration in both cell 
lines; however, this was less than observed for pCXCL8-1.  Using HCMEC/D3 cells 
at 5 nM of pCXCL8-1, neutrophil migration was reduced by ~60% yet at the same 
concentration of pCXCL8-2 this reduction was only ~30% compared to the no 
peptide control; pCXCL8-2 was able to reduce neutrophil migration to the same 
extent as pCXCL8-1 though at a 10 fold higher concentration.  The control peptide 
had no effect on neutrophil migration and showed significant differences compared to 
the test peptide.  There was some variability between cell lines for this peptide, with 
significance being reached at 0.5 nM of peptide in the HBMEC cell line compared to 
a 10 fold higher concentration in the HCMEC/D3 cell line.   
 
pCXCL8-3 significantly reduced neutrophil migration by ~50% at 5, 50 and 500 nM 
(p<0.001) in the HCMEC/D3 cell line, although less than pCXCL8-1 (Supplementary 
Figure 1a).  However, the pCXCL8-4 “dimer” was unable to inhibit CXCL8 induced 
chemotaxis in the HCMEC/D3 cell line (Supplementary Figure 1b).  Due to the 
complications associated with longer peptides during synthesis, the shorter pCXCL8-
1 was chosen in preference as a lead peptide due to the simplicity of its synthesis 
making it advantageous therapeutically.  
 
The peptide based on the unique C-terminal alpha helix of CXCL12γ showed a stark 
decrease of neutrophil migration when compared to its no peptide control in the 
HCMEC/D3 cell line.  This peptide reduced neutrophil migration back to baseline 
levels of ~20% in the HCMEC/D3 cell line at 0.5 nM (p<0.01).  It demonstrated 
potency beyond that of others, requiring as little as 0.0005 nM to significantly reduce 
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neutrophil migration by up to 40%.  The peptide also inhibited neutrophil migration 
significantly more than using the corresponding control peptide at 0.5-50 nM.  Similar 
reduction occurred in the HBMEC cell line although the pattern of inhibition with 
increasing peptide concentration differed between the two cell types.  pCXCL12-1 
was assessed for its ability to reduce CXCL8 mediated neutrophil migration across 
the HCMEC/D3 cell line.  The peptide did not significantly reduce neutrophil 
migration in response to CXCL8 demonstrating some specificity.   
 
pCCL5-3 was unable to reduce monocyte migration across the HCMEC/D3 cell line 
in response to CCL5 and did not differ compared to its corresponding control peptide.  
In agreement, the peptide also showed a similar trend in the HBMEC cell line 
although it did reach significance when compared to CCL5 alone at 5000 nM of 
peptide (p = 0.0039).   
 
Chemokines and peptides based on chemokines bind to human RA synovium. 
To examine if the CXCL8 peptide bound to ECs in situ, fluorescently labelled 
pCXCL8-1 was incubated with human RA synovium, and its binding compared to 
intact CXCL8 labelled with Atto 425.  It has been shown previously that CXCL8 
binding to HS is upregulated in the ECs of human RA synovium (30).  To confirm 
where the positive staining was observed, a double stain was carried out using Von 
Willebrand factor to highlight ECs (in red). pCXCL8-1 (Figure 5A) and CXCL8 
(Figure 5D) were found to associate with blood vessels, and also with the 
extracellular matrix (Figure 5B&E). Staining was absent in the negative control 
sections in the absence of primary antibody, fluorescent CXCL8 or pCXCL8-1 
(Figure 5G&H).   
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The peptide pCXCL8-1 competes with CXCL8 binding  
Having confirmed that both the peptide pCXCL8-1 and CXCL8 bind to RA 
synovium, the question remained whether the peptide competes with CXCL8 for HS 
binding.  Serial sections of human RA synovia were used to assess fluorescent 
CXCL8 binding (Figure 6A), heparanase treatment prior to CXCL8 binding (Figure 
6D) and an equimolar concentration of pCXCL8-1 (0.5 nM) together with CXCL8 
(Figure 6G).  The representative images seen in Figure 6A and B show that CXCL8 
(in green) is associated with ECs stained using Von Willebrand antibody (in red).  
However, when the synovial sections were pre-treated with heparanase I&III prior to 
the addition of CXCL8, there was loss of CXCL8 binding (Figure 6D).  Additionally, 
when equimolar concentrations of labelled CXCL8 and unlabelled pCXCL8-1 were 
added to the sections, a similar loss of CXCL8 binding was observed (Figure 6G).  
This behaviour is consistent with competitive binding of the peptide pCXCL8-1 and 
CXCL8 for HS.   
 
The ability of pCXCL8-1 to inhibit binding of CXCL8 to HS was also evaluated 
using GAG binding plates in an ELISA-like competition assay (Figure 6M).  As 
expected, given its highly positively charged nature, pCXCL8-1 clearly competed 
with CXCL8.  The amount of CXCL8 binding was reduced by all concentrations of 
pCXCL8-1 and this reached significance at 50 nM (p<0.05), reducing the amount of 
CXCL8 binding by at least 40%.  In order to examine this competitive effect on ECs, 
fluorescently labelled CXCL8 and a range of concentrations of unlabelled pCXCL8-1 
were added to HCMEC/D3 cells and the amount of CXCL8 binding was quantified by 
flow cytometry.  As can be seen in Figure 6N, the amount of CXCL8 binding to 
HCMEC/D3s was reduced in a dose-dependent manor over 0.5-50 nM (p < 0.001).  
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pCXCL8-1aa reduces disease severity and acts as an anti-inflammatory in AIA 
mouse model 
Based on its success at reducing neutrophil migration in vitro and its higher affinity 
for HS than WT CXCL8, pCXCL8-1 could possess anti-inflammatory properties.  By 
competing with chemokines for GAG binding, this peptide could diminish the ability 
of chemokines to recruit leukocytes to a site of inflammation.  Consequently, the anti-
inflammatory and therapeutic capability of pCXCL8-1aa was tested in an antigen 
induced (AIA) mouse model of arthritis.  The AIA model shares many 
histopathological and clinical similarities to human RA (41, 42) making it a useful 
and relevant model to investigate our peptide. AIA was induced in the right stifle joint 
of mice and pCXCL8-1aa and corresponding control peptide was injected 6 hours 
later; when swelling routinely appears in AIA mice and so mimics the early condition 
in humans. 
Histologically AIA was characterised by infiltration of the synovial sub-lining by 
leukocytes including neutrophils and exudate containing leukocytes in the joint 
cavity, hyperplasia of the synovial lining and loss of PGs from the articular cartilage 
(images not shown) as observed in haematoxylin/eosin stained sections (Figure 7A, D 
and G respectively). These changes did not occur in contralateral knee joints which 
were injected with PBS instead of mBSA and appeared histologically normal (Figure 
7C, F and I). The inflammation, exudate and hyperplasia appeared less severe in 
pCXCL8-1aa treated mice when compared to the corresponding control peptide 
(Figure 7B, E and H). To quantitate these changes, the parameters were scored as a 
measure of disease severity and differences between peptide and control peptide 
treated mice were evident.  At day 7 post injection leukocyte infiltration (p=0.03), 
cellular exudate (p=0.012) and hyperplasia (p=0.009) were reduced with pCXCL8-1aa.  
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When all histological parameters were pooled to give an overall arthritic index, as a 
measure of overall disease severity, pCXCL8-1aa significantly improved the arthritic 
score when compared to the control peptide at day 7 post injection of mBSA (p = 
0.008).  Differences were not observed at day 3.  A similar trend was observed for 
serum levels of TNFα in AIA mice (Figure 7J).  Concentrations of TNFα were 
reduced at both time points yet reached significance at day 7 post injection of mBSA.   
To determine if pCXCL8-1aa could alter neutrophil infiltration into the synovium, the 
number of these cells were counted in synovial sections (Figure 7K). At 7 days after 
arthritis induction, pCXCL8-1aa reduced the numbers of neutrophils in the synovium 
from 5.6  1.1 to 3.1  0.8 with pCXCL8-1caa (p<0.05). At 3 days after arthritis 
induction there was no significant effect.  
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Discussion 
A recent shift in the interest of the chemokine system as a therapeutic target has 
focussed on GAGs.  Their strong involvement in many disease areas shows potential 
for the development of glycan targeting therapeutics.  In this study, we have 
contributed to this development by showing that peptides based on chemokines can 
act as potential anti-inflammatories.  Due to the presence of GAG binding domains 
within the peptides and the undoubted interaction with negatively charged GAGs, a 
central question was formed.  Do the peptides based on chemokines actively compete 
with chemokines for GAG binding thereby reducing the amount of chemokine being 
bound and presented; and therefore, do they inhibit chemokine induced leukocyte 
migration and reduce disease severity?  Based on the necessity of chemokine binding 
to GAGs for exerting biological functions in vivo, there is a clear rationale for 
exploiting the chemokine - GAG interaction.  Our peptide design approach takes 
advantage of the enriched HS-binding domains of chemokines and uses the discrete 
pocket of highly charged residues as novel anti-inflammatory peptides.   
 
As our approach is intended to keep as close to the natural WT protein, no new GAG 
binding sites at different locations of the chemokine have been introduced and the 
peptides exhibit sequence identity with each of the chemokines they are based upon.  
We intend that this would prevent interference with hydrogen bonding and Van der 
Waals forces in order to maintain the chemokines in built specificity for the GAG.  If 
maintenance of hydrogen bonding and hydrophobic forces can be achieved, this 
approach could be a novel and effective way to create efficient and selective GAG 
antagonists as this is what creates the specificity between chemokines and GAGs (43).  
Utilising the HS binding domain of chemokines as small chain peptides (lead peptide 
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is 10 amino acids) is a new approach to combating the chemokine – GAG interaction. 
Previous approaches have incorporated much  more of the chemokine structure with 
knocked out GPCR activation and have included an unnatural sequence in order to 
increase the binding affinity of the peptide to GAGs, yet offering increased potential 
for off-target effects (44).  A further advantage of the current novel therapeutic 
approach is the predictable mechanism by which the peptide works.  The peptides 
based on chemokines interact with GAGs and compete with the WT chemokine for 
GAG binding.  The peptide based on CXCL8 could compete with CXCL8 for binding 
to HS on binding plates, EC lines and ECs in RA tissue.  The binding was associated 
with EC GAGs as when either ECs or RA tissue were treated with an enzyme to 
degrade the HS, the binding was visibly reduced.  Furthermore, control peptides 
lacking amino acids that interact with GAGs, such as lysine and arginine, bound 
significantly less to ECs which agreed with binding isotherm data where the control 
peptides showed little interaction with HS.  This suggests that the interaction of the 
peptides that do have the lysine and arginine amino acids are in fact interacting with 
the GAGs present on the EC, and these amino acids are important in the interaction.  
As GAG expression differs between tissues, especially in inflamed tissue where 
chemokine binding sites on ECs are up-regulated (40), the peptide could bind to 
GAGs preferentially in the inflamed tissue and prevent further chemokine induced 
leukocyte migration. 
 
As a control for our experiments, all peptides were subject to chemotaxis assays 
whereby the peptide only was placed in the basal chamber and leukocytes were 
allowed to migrate across an endothelial layer.  These peptides did not induce 
chemotaxis of leukocytes and leukocyte migration remained at baseline (data not 
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shown).  This suggests no functional role of the peptides other than to act as GAG 
binding antagonists of WT chemokines.  Our peptide design approach is clearly 
dependent upon the knowledge of the GAG-binding site in the target protein which 
were based on published data.  Using these data, we synthesised control peptides 
which lack the reported HS binding residues and were replaced with a non-charged 
amino acid.  These control peptides were fundamental in distinguishing anti-
inflammatory properties of peptides in vitro and in vivo.   
 
Our peptides were subjected to experiments to assess binding to soluble GAGs.  As an 
initial assessment of peptide interaction with soluble GAGs, they were tested for their 
binding affinities to HS and DS by IFT.  These two GAGs were chosen to show any 
selectivity by the peptide for particular GAGs.  A binding isotherm of WT CXCL8 
was measured and peptides based on CXCL8 were compared.  In agreement with the 
literature, WT CXCL8 binds with higher affinity to HS than DS (21, 30).  This 
preference is also apparent for the CCL5 peptide whereas the CXCL12 peptide shows 
equal preference for HS and DS.  In all cases of peptides based on CXCL8, the 
peptides had a higher affinity than WT CXCL8 for HS and DS. These increased 
binding affinities of CXCL8 peptides compared to WT CXCL8 shows that the simple 
peptide design using only identical sequences within chemokines is sufficient to 
induce a competitive antagonist, perhaps even posing as safe biological molecules 
based on their natural design.  The high fluorescence quenching value (as indicated on 
the y axis in Figure 2) refers to more efficient fluorescence deactivation and thus to 
tighter binding of the GAG ligand.  This is especially true of pCXCL12-1 where 
quenching occurs in the first additions of GAG ligand and reaches a quenching value 
up to 80%.  The interaction could be electrostatic in nature however when the salt 
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level of the solution is increased from physiological levels (137 mM to 400 mM), the 
affinity of this peptide for HS remains similar (data not shown).  This is indicative of 
a specific peptide – HS interaction.  Taken together, these data show a strong affinity 
of the peptides for GAGs (in the low nM range) making them viable antagonistic 
molecules.  Furthermore, different peptides show selectivity in targeting particular 
GAGs. 
 
Using an antibody to a HS epitope, we found HS to be present on EC cell lines used 
in this study, occurring as a mesh-like structure.  Confirmation of this expression was 
achieved with heparanases; when the ECs were incubated with both heparanase I and 
III, the expression of HS was reduced to background.  HS on ECs has been widely 
reported to bind, concentrate and present chemokines to leukocytes during 
extravasation (24, 27, 34, 45).  Indeed, we have shown that CXCL8 binding to ECs is 
reduced when the cells are treated with heparanases alongside the fact that our control 
peptide pCXCL8-1c shows little interaction with ECs corroborates HS as a key player 
in chemokine activity.  The implications of this are clearly shown in 
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Figure 3E where neutrophil transmigration through an endothelial monolayer that has 
been pre-treated with heparanases is vastly reduced.   
 
Using our peptides based on chemokines, we were able to show a reduction of 
leukocyte migration in a cell culture model of inflammation.  By placing chemokine 
in the basal chamber, the chemokine would be transcytosed or diffuse to the EC 
surface thereby creating a chemotactic gradient for the leukocytes placed into the 
apical chamber (27).  The peptides were tested in two separate cell lines to confirm 
results.  Peptides based on CXCL8 (apart from pCXCL8-4) were able to reduce 
leukocyte transendothelial migration.  Interestingly, in agreement with IFT binding 
affinity data, the smaller pCXCL8-1 peptide with 3 HS binding sites showed 
increased efficacy and was most efficacious in the low nanomolar range unlike 
pCXCL8-2 which has 4 HS binding domains and required a higher concentration to 
elicit similar results.  pCXCL8-3 could inhibit CXCL8 induced neutrophil migration 
from 0.5nM to 5000nM however the optimum concentration was 500nM and 
therefore much higher than pCXCL8-1.  Conversely pCXCL8-4 showed no anti-
chemotactic ability in vitro. Our results suggest that the two lysine and one arginine 
residues in the final 10 amino acids of the C-terminus of CXCL8 are especially 
important in its functional interaction with HS in terms of driving leukocyte 
migration.  In addition, there is specificity in the interaction since adding the 
CXCL12 peptide instead of CXCL8 peptide had no inhibitory effect on CXCL8 
driven neutrophil migration, despite the increased affinity of this peptide for HS as 
shown by IFT. Therefore, the CXCL8 peptide binding site on HS may be different 
from that of the CXCL12 peptide. 
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Our peptide utilising the C-terminus of CXCL12γ was highly potent and showed a 
marked decrease in neutrophil transendothelial migration compared to a control.  
However, unlike some of the other peptides, a difference between cell lines was 
observed.  In addition, the pCXCL12-1 peptide shows specificity in action as it was 
unable to inhibit CXCL8 induced neutrophil migration. The peptide based on CCL5 
showed promising IFT data with a high affinity for HS however this did not translate 
into success in vitro.  pCCL5-3 was unable to exhibit an anti-chemotactic effect on 
mononuclear cells using HCMEC/D3 cells and a very small effect using HMBECs.  
This could be due to a number of different reasons, one being the very small size of 
the peptide (Mr = 773) or perhaps that mononuclear cell migration is through an 
alternative mechanism.  As we’ve shown, heparanase treatment does not have as 
extensive a reduction of CCL5 mediated leukocyte migration as it does on CXCL8 
migration.  This suggests a role for perhaps another GAG or a molecule like the Duffy 
antigen receptor for chemokines (DARC) whose role is less clear in chemokine 
presentation to leukocytes. 
 
The results show that CXCL8 binds to RA synovium, as does the peptide pCXCL8-1.  
The pattern of binding was similar to that of HS staining (30), being associated with 
blood vessels, and some was observed in the extracellular matrix.  Studies have 
previously shown similar CXCL8 binding which was attributable to the presence of 
HSPGs on ECs and the extracellular matrix (30).  It was investigated if pCXCL8-1 
could compete for CXCL8 binding to GAGs in cultured ECs and RA synovia.  We 
clearly demonstrated a reduction in CXCL8 binding in the presence of peptide, 
moreover the binding is HS dependent as the use of heparanases also reduces CXCL8 
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binding.  In addition, the competitive nature of pCXCL8-1 was shown in HS binding 
plates in an ELISA like assay, despite the varying concentrations used which was 
necessitated by the different techniques.   
 
Following effects in vitro and in situ, our lead peptide pCXCL8-1 was evaluated in an 
AIA murine model after modifications to render it less susceptible to proteolytic 
degradation (pCXCL8-1aa).  Previous work has validated this model as suitable to test 
therapeutic agents that interfere with the CXCL8 axis (46) as the model’s pathology is 
driven by the mouse functional homologue of CXCL8.  We have shown that 
pCXCL8-1aa was able to reduce several parameters involved in arthritis, significantly 
reducing the overall arthritic score as a measure of disease severity.  The reduction 
was characterised by reduced leukocyte infiltrate into the synovium and joint space, 
particularly including neutrophils.  Neutrophils are considered influential cells in the 
development of inflammatory joint disease, as supported by several studies involving 
experimental models of arthritis.  Neutrophils are found in high numbers within the 
human rheumatoid joint where they play a significant role in inflicting damage to the 
tissue, bone and cartilage by secretion of proteases and toxic oxygen species, as well 
as driving further inflammation through secretion of cytokines, chemokines and 
prostaglandins (47).  This suggests that targeting CXCL8 driven neutrophil 
extravasation with CXCL8 peptides is successful and beneficial.  Furthermore, it is 
possible that inhibiting a mainly neutrophil attracting chemokine (CXCL8) can have a 
direct or indirect effect on other cells and pathological features of RA.  Hyperplasia of 
the synovial lining layer occurs in RA and is proposed to occur via the recruitment of 
monocytes in the sub-lining blood vessels which then migrate and insert into the 
lining layer (48, 49).  Here, the monocytes are activated and differentiate into 
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macrophages and undergo hyperplasia.  Monocyte adherence to the endothelium is 
increased by the presence of CXCL8 and so by reducing the amount of CXCL8 
presentation, the peptide may be able to reduce monocyte recruitment and hence 
hyperplasia of the lining layer. By reducing neutrophil recruitment, it is possible that 
recruitment of other cell types via reduced chemokine and cytokine production such 
as TNFα is also reduced.  Here we show that pCXCL8-1aa reduces the levels of TNFα 
in the circulation of AIA mice.  TNFα is a central cytokine involved in inflammation 
and tissue degradation in RA and blocking this cytokine is the major current therapy 
for the disease.  The decrease in TNFα levels suggest that administration of pCXCL8-
1 can reduce systemic inflammation, which is a feature of RA, in addition to having 
local effects in the joint. 
 
In summary, GAGs are an abundant class of highly sulphated polysaccharides that are 
known to drive and control protein activity by interacting with basic amino acids on 
the target protein.  We have targeted this functional interaction as a potential way of 
antagonising the target protein’s pathological role.  Chemokines are clearly beneficial 
in the battle against infectious organisms and during wound healing after tissue injury, 
yet excessive and on-going chemokine expression has been associated with 
inflammatory disorders, characterised by an inappropriate increase in leukocyte 
infiltration (50).  The chemokine system, therefore, seems an attractive target for 
modulating such diseases.  Interestingly, other species have already manipulated the 
chemokine system to their own benefit.  For example, viruses and ticks have 
successfully used this strategy to evade the host’s immune system (51) by producing 
homologues of chemokines and chemokine receptors thereby altering and controlling 
their activity.  The chemokine system has been the subject of therapeutic interest for 
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many years with previous strategies focussing on chemokine receptor antagonists 
(52).  Unfortunately, the labours of this train of thought have been largely 
unsuccessful in clinical trials.  More recent strategies have employed the use of the 
chemokine - GAG interaction.  The recently developed CellJammer approach seeks to 
develop mutant chemokines with increased GAG binding affinity and knocked out 
GPCR function, thus creating an antagonist for WT chemokines.  This approach has 
been successfully applied to create antagonists for CXCL8 and CCL2 (46, 53).  
CXCL8 and CCL2 based “decoy” molecules were shown to moderate inflammation 
in various mouse models such as ischemia/reperfusion, AIA, renal allograft rejection 
and experimental autoimmune uveitis.  Most recently, a C-terminal peptide based on 
CXCL9 was shown to inhibit neutrophil extravasation and monosodium urate crystal 
induced gout in mice (54).  The amounting evidence in support for the chemokine - 
GAG strategy is compelling.  Our approach, although similar to these recent studies, 
is a simplified and more natural design.  Our lead peptide is a mere 10 amino acids in 
length making it a quick, cheap and easy molecule to synthesise therapeutically.  Not 
only this but the data gathered confirms the chemokine - GAG interaction as a 
biologically relevant target.   
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Tables 
Table 1:  Peptides and control peptides showing sequences and molecular weight. 
 
 
 
 
 
 
 
 
aa = amidated & acetylated 
c = control 
p = peptide 
 
Peptide Sequence Molecular	Weight
pCXCL8-1 63EKFLKRAENS72 1220
pCXCL8-1c 63EAFLGSAENS72 1024
pCXCL8-1aa Ac-
63EKFLKRAENS72-NH2 1262
pCXCL8-1caa Ac-
63EAFLGSAENS72-NH2 1065
pCXCL8-2 58VQRVVE KFLKRAENS72 1803
pCXCL8-2c 58VQAVVE AFLGSAENS72 1520
pCXCL8-3 20KFIK ELRVIESGPH CANTEIIVKL SDGRELCLDP KENWVQRVVE 
KFLKRAENS72
6167
pCXCL8-4 55ENWVQRVVE KFLKRAENS72 GSGSG 55ENWVQRVVE KFLKRAENS72 4792
pCCL5-1 44RKNR47 572
pCCL5-2 43TRKNR47 673
pCCL5-3 42VTRKNR47 773
pCCL5-3c 42VTGSGS47 506
pCXCL12-1 68GRREEKVGKKE KIGKKKRQKK RKAAQKRKN98 3620
pCXCL12-1c 68GRREEKVGGSG SIGGSGSQGS GSAAQKRKN98 2889
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Table 2: Affinity of peptides for HS and DS 
Peptide/Protein Heparan Sulphate (HS) Dermatan Sulphate (DS) 
 Kd (nM) ± SD Kd (nM) ± SD 
WT fCXCL8 128 5 170 13 
fpCXCL8-1 15 3 44 3 
fpCXCL8-2 61 5 52 3 
fpCXCL8-1aa 65 4 45 2 
fpCCL5-3 8 1 148 7 
fpCXCL12-1 2 0.5 3 0.2 
 
aa = C-terminal amidation 
f = FITC labelled 
p = peptide 
WT = wildtype 
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Table 3:  Scores from each histological parameter at day 3 and day 7 of AIA. 
 
 
 
 
 
 
*p<0.05, **p<0.01 compared to control peptide. 
aa = amidated & acetylated 
c = control 
p = peptide 
Timepoint Peptide Hyperplasia Synovial	
Infiltrate
Exudate Cartilage	
depletion
Arthritic	
Index
Day	3
pCXCL8-1aa 2	± 0.3 2.9	± 0.5 2.1	± 0.2 1.2	± 0.5 8.2	± 1.3
pCXCL8-1caa 2	± 0.4 3.3	± 0.5 2.1	± 0.5 0.1	± 0.1 7.4 ± 0.9
Day	7
pCXCL8-1aa 1.4	± 0.2** 1.3	± 0.4* 0.4 ± 0.2* 0.8	± 0.5 3.9	± 0.9**
pCXCL8-1caa 2.6	± 0.3 3.2	± 0.6 1.4	± 0.2 1.5	± 0.5 8.7	± 1.0
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Figure Legends 
Figure 1:  Modelling peptides based on chemokines 
 
(A) Wildtype CXCL8 (B) C-terminal peptides (pCXCL8-1 and -2) indicated in blue 
where -1 is dark blue and -2 is the longer peptide indicated by two blue shades, (C) 
longer peptide (pCXCL8-3) including all known HS binding sites as shown by the 
green and purple structures and the yellow highlighting the N-terminal residues which 
were removed, (D) both C-terminal alpha helices (pCXCL8-4) linked together by a 
pre-modelled linker to form a “dimer”.  (E) Wildtype CCL5. (F) Indicated are 
peptides based on the 40s loop of CCL5 (pCCL5-1 / -2 / -3) with pCCL5-3 being the 
longest indicated by two blue shades and grey, pCCL5-2 two blue shades and pCCL5-
1 dark blue.  (G) Wildtype CXCL12γ. (H) C-terminal peptide (pCXCL12-1) indicated 
in blue. Carbon atoms are seen in green and pink where each represents the 
monomeric unit, oxygen in red, nitrogen in blue and sulphur in yellow (A, E and G).  
Structures are shown as dimers. Please note that CXCL8 and CXCL12 peptides are 
not helical in structure but are based on the helical sequences present in the wildtype 
chemokine.
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Figure 2:  Binding isotherms of peptide interactions with GAGs 
Isothermal fluorescent titration binding of peptide is shown to either HS (black) or DS 
(red).  Control peptide interaction with HS is shown in green. On the y-axis, the 
relative change in fluorescence intensity following ligand addition is displayed: dF = 
F (fluorescence emission at a certain GAG concentration) − F 0 (fluorescence 
emission in the absence of ligand). Kd based on line of best fit taken from the mean of 
three separate experiments ± SD.  
 
Novel anti-inflammatory peptides based on chemokines 
 
 52 
 
Figure 3:  The role of endothelial HS in leukocyte transendothelial migration and 
chemokine/peptide binding. 
HCMEC/D3s were stained with anti-HS 10e4 antibody. (A) HS expression as 
indicated by mesh-work like pattern, (B) plus DAPI. (C) ECs were pre-treated with 
heparanase I&III, (D) plus DAPI. (E) Neutrophil transendothelial migration after EC 
treatment with heparanase I&III in response to CXCL8 stimulus, (F) mononuclear 
transendothelial migration after EC treatment with heparanase I&III in response to 
CCL5 stimulus. HCMEC/D3s were pre-treated with heparanase I&III and the ability 
of chemokine or peptide to bind to the cells was assessed by detection of a fluorescent 
signal by flow cytometry.  (G) CXCL8 binding, (H) pCXCL8-1 binding.  (E-H) Data 
shown are means (n=3) ± SE. **p<0.01, ***p<0.001, ****p<0.0001.  Scale bar = 
20μm for all images. Percentage migration is calculated from the total number of cells 
added. 
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Figure 4:  Anti-chemotactic effects of peptides on leukocyte transendothelial 
migration. 
Anti-chemotactic ability of peptides was tested in HBMEC and HCMEC/D3 cell 
lines.  On the y axis percentage of transendothelial migration in response to increasing 
concentration of peptide (nM) on the x axis.  Indicated (±) is the presence of 100 
ng/ml chemokine.  The effect of the peptide (black) is compared to a control peptide 
(white).  For CXCL8 and CXCL12 peptides neutrophils were used and mononuclear 
cells for the CCL5 peptide.  Data shown are mean transendothelial migration ± SE 
(n=3). *p<0.05, **p<0.01, ***p<0.001 compared to chemokine alone in absence of 
peptide, §p<0.05, §§p<0.01, §§§p<0.001, §§§§p<0.0001. Percentage migration is 
calculated from the total number of cells added. 
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Figure 5:  Peptide pCXCL8-1 and CXCL8s interact with ECs in human RA 
synovium. 
Representative immunofluorescence images of human RA synovium. Von Willebrand 
factor staining is in red highlighting ECs and green represents either pCXCL8-1 or 
CXCL8 positive staining.  (A) pCXCL8-1 binding, (B) Von Willebrand factor, (C) 
DAPI. (D) CXCL8 binding, (E) Von Willebrand factor, (F) DAPI. (G) Negative 
control with no pCXCL8-1 or CXCL8, (H) no Von Willebrand factor, (I) DAPI.  
Arrows indicate positive pCXCL8-1 or CXCL8 staining of blood vessels and in the 
extracellular matrix.  Scale bar = 50 μm for each image.  
 
Novel anti-inflammatory peptides based on chemokines 
 
 55 
 
Figure 6:  The peptide pCXCL8-1 competes with CXCL8 binding. 
Serial sections of human RA synovium were cut and incubated with fluorescent 
CXCL8 (5 µg/ml/0.5 nM) in order to assess binding competition by unlabelled 
pCXCL8-1 (0.5 nM).  (A) CXCL8 binding only, (B) Von Willebrand factor, (C) 
DAPI. (D) CXCL8 binding after treatment with heparanase I&III.  (G) CXCL8 
binding with the addition of equimolar pCXCL8-1.  J-L is the negative control in the 
absence of fluorescent CXCL8, pCXCL8-1 or Von Willebrand antibody.  Scale bar = 
50 μm for each image.  (M) To assess whether pCXCL8-1 could compete with 
CXCL8 for HS binding, GAG binding plates in an ELISA-like assay were used to 
evaluate a reduction of CXCL8 binding with a dose dependent increase of pCXCL8-
1.  (N) In a similar experiment, HCMEC/D3 cells were treated with Atto 425 labelled 
CXCL8, an increasing dose of pCXCL8-1 was added and the CXCL8 signal detected 
by flow cytometry. Data shown are means ± SE (n=3).  *P<0.05, ***p<0.001 
compared to the negative control in the absence of peptide. 
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Figure 7:  Murine antigen induced arthritis. 
Arthritis was induced by intra-articular injection of methylated BSA in the right knee 
(stifle) joint followed by intra-articular injection of 5μg pCXCL8-1aa or pCXCL8-1caa 
6 hours later. For a non-arthritic control, PBS was injected into the left knee joint. (A-
I) Representative histological images stained with H&E.  (A) pCXCL8-1caa treated 
joint showing synovial infiltrate (as indicated by *), inset shows detail of cell infiltrate 
containing neutrophil population (scale bar = 20 μm), (B) pCXCL8-1aa, (C) PBS 
control. Images showing synovial exudate (as indicated by arrow) in (D) pCXCL8-
1caa, (E) pCXCL8-1aa, (F) PBS control; Scale bar = 200 μm in each image.  Images 
showing synovial hyperplasia (as indicated by arrow) in (G) pCXCL8-1caa, (H) 
pCXCL8-1aa, (I) PBS control; Scale bar = 40 μm in each image. (J)  Serum 
concentrations of TNFα were analysed by ELISA.  (K) The effect of pCXCL8-1aa on 
neutrophil infiltration in the synovium in comparison to pCXCL8-1caa. Neutrophils 
were quantified by counting cell numbers in 5 random fields of view in H&E sections 
at x1000 magnification. Data shown are means ± SE (n=5 mice), *p<0.05. 
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Supplementary Figure 1: Anti-chemotactic effects of pCXCL8-3 and pCXCL8-4 on 
leukocyte transendothelial migration. 
Anti-chemotactic ability of peptides was tested in HCMEC/D3 cells.  On the y axis 
percentage of neutrophil transendothelial migration in response to increasing 
concentration of peptide (nM) on the x axis.  Indicated (±) is the presence of 100 
ng/ml chemokine. Data shown are mean transendothelial migration ± SE (n=3). 
**p<0.01, ***p<0.001 compared to chemokine alone in absence of peptide, 
§§p<0.01, §§§p<0.001. Percentage migration is calculated from the total number of 
cells added. 
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Figure 5 
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Figure 6 
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Figure 7 
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